bendamustine

Bendamustine (SDX105) for the treatment of Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Bendamustine-D4 is the deuterium-labeled Bendamustine. Bendamustine is a DNA cross-linking compound with alkylating and antimetabolite properties. Bendamustine causes DNA breaks.

Bendamustine hydrochloride (EP-3101) (IC50 of 50 μM) is an alkylating agent associated with DNA damage.

N-DesmethylBendamustine is a metabolite of Bendamustine. It exerts cytotoxic effects on various lymphoma cell lines and peripheral blood lymphocytes.

Bendamustine-[D8] Hydrochloride (Standard) is a reference standard of Bendamustine-[D8] Hydrochloride intended for quantitative analysis, quality control, and related biochemical research applications.

Polatuzumab vedotin-piiq is an antibody-drug conjugate targeting CD79b, obtained by conjugating a humanized anti-CD79b monoclonal antibody to the potent microtubule inhibitor monomethyl auristatin E (MMAE). Polatuzumab vedotin shows important application prospects in research related to large B-cell lymphoma (LBCL).